ICI, which blocks the binding of checkpoint proteins with their partner proteins and allows T cells to kill cancer cells, has been revolutionarily developed, since Yervoy, the first ICI and CTLA-4 inhibitor, was approved by the U.S. FDA in 2011. Here, CTLA4 is linked to cancer.